A booster of Johnson & Johnson’s Covid-19 vaccine showed signs of significantly bolstering the immune defenses of study subjects, federal health regulators said Wednesday. The regulators cautioned, however, that data was limited and they had to rely on J&J’s own analysis for some of the study findings, rather than conducting their own. The Food and Drug…

Johnson & Johnson said Tuesday that the company had submitted data to the Food and Drug Administration to support the use of a booster dose of its Covid-19 vaccine. The announcement comes two weeks after the company presented the results of a randomized, controlled Phase 3 study showing that a booster dose given two months after…

Data released Tuesday from a late-stage clinical trial showed that study participants in 10 countries including the U.S. who received a second dose of the company’s vaccine two months after the first had 75% protection against symptomatic Covid-19. Participants in the U.S. had 94% protection against the illness. J&J didn’t explain the reason for the…

The makers of the Pfizer-BioNTech vaccine will soon ask regulators for clearance its use in children 5 years and over, and are getting ready to make smaller doses of the vaccine for younger children, according to one of the founders of BioNTech, the German company that developed the vaccine in partnership with Pfizer. “We will be presenting the…